Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

NCT07482605 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)
Malignant Pleural Effusions (Mpe)- Pleurodesis

Interventions

DRUG: Furmonertinib
RADIATION: Thoracic Radiotherapy (TRT)

Sponsor

Jiangmen Central Hospital